Anti-inhibitor coagulant complex is a medication used to control bleeding episodes and prevent bleeding episodes in hemophilia A and B. Anti-inhibitor coagulant complex, also known as FEIBA (factor eight inhibitor bypassing activity), contains several proteins involved in the prothrombinase complex.
- Mechanism
- Curator reviewed · 2 references
Factor VIIa present in FEIBA forms a complex with tissue factor and calcium which converts endogenous and FEIBA contained factor X to Xa. Endogenous and FEIBA contained factor Xa act as parrt of the prothrombinase complex to convert endogenous and FEIBA contained prothrombin to thrombin. Endogenous and FEIBA contained thrombin then cleave fibrinogen to insulouble fibrin and activate factor XIII which covalently cross-links fibrin to form a polymer mesh. FEIBA also contains factor IX and IXa which act as part of the tenase complex to convert factor X to Xa. Thrombin activates factor V, VII, and VIII as part of the amplification phase of the clotting cascade. These events promote the formation of blood clots to prevent or stop bleeding.
- Primary indication
- For use in the control of bleeding episodes, perioperative management, and routine prophylaxis against bleeding episodes in hemophilia A and B patients with inhibitors.Curator reviewed · 6 structured indications
- First approval
- Canada, 2020 · United States, 1986
- Also known as
- Activated prothrombin complex concentrate · Antiinhibitor coagulant complex · Factor Eight Inhibitor Bypassing Activity · Factor VIII bypassing fraction · Factor VIII inhibitor bypassing activity
- Brand names
Resolves to
What you can answer from here — as of November 11, 2025
Which drugs share a target with Anti-inhibitor coagulant complex, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account